−0.38PLN
−39.28 MPLN
162.62 MPLN
21.03 M
About CLNPHARMA
Sector
CEO
Maciej Wieczorek
Headquarters
Lomianki
Website
Employees (FY)
523
Founded
2002
ISIN
PLCLNPH00015
FIGI
BBG00DSJ1T59
Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm's products include Aromek, Donepex, Ketrel, Salmex, and Valzek. It operates through the Generic Drug and Innovative segments. The Generic Drug segment pertains to the manufacture and sale of drugs registered and authorized for marketing. The Innovative segment involves activities that develop the documentation on the basis of which a drug could be registered or commercialized at the stage prior to drug registration. The company was founded by Maciej Wieczorek on June 20, 2002 and is headquartered in Lomianki, Poland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CLN is 14.80 PLN — it has decreased by 1.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on GPW exchange CLNPHARMA stocks are traded under the ticker CLN.
One year price forecast for CLNPHARMA has a max estimate of 23.00 PLN and a min estimate of 12.00 PLN.
CLNPHARMA revenue for the last quarter amounts to 48.80 M PLN despite the estimated figure of 52.15 M PLN. In the next quarter revenue is expected to reach 54.10 M PLN.
Yes, you can track CLNPHARMA financials in yearly and quarterly reports right on TradingView.
Like other stocks, CLN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLNPHARMA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 523.00 employees. See our rating of the largest employees — is CLNPHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLNPHARMA EBITDA is −19.87 M PLN, and current EBITDA margin is −15.78%. See more stats in CLNPHARMA financial statements.